Cardinal Health shares rose 2.6% this afternoon to a price of $203.06. The stock is still trading within range of its average target price of $211.43, and over the last 52 weeks, it has recorded a 64.2% performance. Analysts have given the Large-Cap Pharmaceutical stock target prices ranging from $167.0 to $232.0 dollars per share, with an average rating of buy.
The stock has an average amount of shares sold short at 3.2%, and a short ratio of 2.66. The company's insiders own 0.25% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 88.6% of Cardinal Health's shares being owned by this investor type.
Institutions Invested in Cardinal Health
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-06-30 | Vanguard Group Inc | 13% | 30,575,816 | $6,208,725,122 |
| 2025-06-30 | Blackrock Inc. | 13% | 30,547,864 | $6,203,049,189 |
| 2025-06-30 | State Street Corporation | 5% | 12,673,128 | $2,573,405,340 |
| 2025-06-30 | Geode Capital Management, LLC | 3% | 6,389,049 | $1,297,360,274 |
| 2025-06-30 | FMR, LLC | 3% | 6,274,918 | $1,274,184,833 |
| 2025-06-30 | Morgan Stanley | 2% | 5,473,471 | $1,111,443,007 |
| 2025-06-30 | Bank of America Corporation | 1% | 3,481,193 | $706,891,042 |
| 2025-06-30 | NORGES BANK | 1% | 3,478,693 | $706,383,392 |
| 2025-06-30 | Invesco Ltd. | 1% | 3,037,782 | $616,852,005 |
| 2025-06-30 | Northern Trust Corporation | 1% | 2,994,363 | $608,035,343 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Cardinal Health.
